Drug Profile
Research programme: non-alcoholic steatohepatitis therapeutics - Evotec SE
Alternative Names: NASH therapeutics - Evotec SE; TargetNASH programme - Evotec SELatest Information Update: 28 Jul 2020
Price :
$50
*
At a glance
- Originator Evotec AG
- Developer Evotec SE
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Non-alcoholic steatohepatitis
Most Recent Events
- 28 Jul 2020 No recent reports of development identified for research development in Non-alcoholic-steatohepatitis in Germany
- 29 Jun 2016 Early research in Non-alcoholic steatohepatitis in Germany (unspecified route)